Please provide your email address to receive an email when new articles are posted on . Despite similar procedural success, percutaneous mitral valve repair for post-MI mitral regurgitation was ...
CHICAGO, IL—Eagerly awaited results from two percutaneous mitral valve edge-to-edge repair trials are finally cresting the horizon. It’s confirmed: MITRA-FR will be released at the 2018 European ...
Although patients with mitral regurgitation (MR) who are treated with percutaneous repair are more likely than those who receive surgery to require a second procedure in the first year, long-term ...
TEWKSBURY, Mass.--(BUSINESS WIRE)--Mitralign, Inc., an innovative provider of percutaneous valve repair solutions, today announced that the U.S. Food and Drug Administration has granted ...
A prospective study of patients whose acute Achilles tendon ruptures were sutured percutaneously showed that the new technique produced functional outcomes comparable to tendons repaired open and with ...
A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter ...
TEWKSBURY, Mass.--(BUSINESS WIRE)--Mitralign Inc. (Mitralign), a privately held medical device company, announced the first U.S. subject has been enrolled in the SCOUT Study using the company’s ...
A substantial proportion of healthy men and women had detectable valvular regurgitation by color Doppler echocardiography. Population-based studies using color Doppler show a wide range of detectable ...
(Philadelphia, PA and New Orleans, Louisiana) – The Hospital of the University of Pennsylvania (HUP) is participating in a nationwide clinical trial of a new valve repair device that could replace ...
Mitralign Inc., a cardiovascular device company, today reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation (TR). Prof. Dr. med.
Peter C. Block, M.D., F.A.C.C.; Athena Poppas, M.D., F.A.C.C. While all patients had moderate (3+) to severe (4+) MR at baseline, 64% of patients discharged with a clip had MR ≤2 after 1 month, which ...